Your browser doesn't support javascript.
loading
Designing clinical trials based on modern imaging and metastasis-directed treatments in patients with oligometastatic breast cancer: a consensus recommendation from the EORTC Imaging and Breast Cancer Groups.
Pasquier, David; Bidaut, Luc; Oprea-Lager, Daniela Elena; deSouza, Nandita M; Krug, David; Collette, Laurence; Kunz, Wolfgang; Belkacemi, Yazid; Bau, Maria Grazia; Caramella, Caroline; De Geus-Oei, Lioe-Fee; De Caluwé, Alex; Deroose, Christophe; Gheysens, Olivier; Herrmann, Ken; Kindts, Isabelle; Kontos, Michalis; Kümmel, Sherko; Linderholm, Barbro; Lopci, Egesta; Meattini, Icro; Smeets, Ann; Kaidar-Person, Orit; Poortmans, Philip; Tsoutsou, Pelagia; Hajjaji, Nawale; Russell, Nicola; Senkus, Elzbieta; Talbot, Jean-Noël; Umutlu, Lale; Vandecaveye, Vincent; Verhoeff, Joost J C; van Oordt, Willemien Menke-van der Houven; Zacho, Helle D; Cardoso, Fatima; Fournier, Laure; Van Duijnhoven, Frederieke; Lecouvet, Frédéric E.
Affiliation
  • Pasquier D; Academic Department of Radiation Oncology, Centre Oscar Lambret, Lille, France; University of Lille and CNRS, Centrale Lille, UMR 9189-CRIStAL, Lille, France. Electronic address: d-pasquier@o-lambret.fr.
  • Bidaut L; College of Science, University of Lincoln, Lincoln, UK.
  • Oprea-Lager DE; Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.
  • deSouza NM; The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, Sutton, UK.
  • Krug D; Department of Radiation Oncology, Universitaetsklinikum Schleswig-Holstein-Campus Kiel, Kiel, Germany.
  • Collette L; Former European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium.
  • Kunz W; Department of Radiology, University Hospital, LMU Munich, Munich, Germany.
  • Belkacemi Y; AP-HP, Radiation Oncology Department, Henri Mondor University Hospital, Créteil, France; INSERM Unit 955 (-Bio), IMRB, University of Paris-Est (UPEC), Créteil, France.
  • Bau MG; Azienda Ospedaliera Città della Salute e della Scienza di Torino, Ospedale Sant'Anna, Turin, Italy.
  • Caramella C; Hôpital Marie Lannelongue, Groupe Hospitalier Paris Saint-Joseph, Paris, France.
  • De Geus-Oei LF; Department of Radiology, Leiden University Medical Center, Leiden, Netherlands; Biomedical Photonic Imaging Group, University of Twente, Enschede, Netherlands; Department of Radiation Science and Technology, Delft University of Technology, Delft, Netherlands.
  • De Caluwé A; Radiotherapy Department, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
  • Deroose C; Nuclear Medicine, University Hospitals Leuven, Leuven, Belgium.
  • Gheysens O; Department of Nuclear Medicine, Institut de Recherche Expérimentale et Clinique (IREC), Cliniques Universitaires Saint-Luc, Institut du Cancer Roi Albert II, UCLouvain, Brussels, Belgium.
  • Herrmann K; Department of Nuclear Medicine, University of Duisburg-Essen, Essen, Germany; German Cancer Consortium (DKTK), University Hospital Essen, Essen, Germany.
  • Kindts I; Department of Radiation Oncology, Cancer Centre, General Hospital Groeninge, Kortrijk, Belgium.
  • Kontos M; National and Kapodistrian University of Athens, Athens, Greece.
  • Kümmel S; Breast Unit, Kliniken Essen-Mitte, Essen, Germany; Charité - Universitätsmedizin Berlin, Department of Gynecology with Breast Center, Berlin, Germany.
  • Linderholm B; Department of Oncolgy, Sahlgrenska University Hospital, Gothenburg, Sweden; Institution of Clinical Sciences, Department of Oncology, Sahlgrenska Academy at Gothenburg University, Gothenburg , Sweden.
  • Lopci E; IRCCS Humanitas Research Hospital, Milan, Italy.
  • Meattini I; Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy; Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero Universitaria Careggi, Florence, Italy.
  • Smeets A; Department of Surgical Oncology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
  • Kaidar-Person O; Oncology Institute, Sheba Tel Hashomer, Ramat Gan, Israel; Tel-Aviv University, Tel-Aviv, Israel.
  • Poortmans P; Department of Radiation Oncology, Iridium Netwerk, Antwerp, Belgium; University of Antwerp, Antwerp, Belgium.
  • Tsoutsou P; Hôpitaux Universitaires de Genève, Site de Cluse-Roseraie, Geneva, Switzerland.
  • Hajjaji N; Medical Oncology Department, Centre Oscar Lambret, Lille, France; Laboratoire Protéomique, Réponse Inflammatoire, et Spectrométrie De Masse (PRISM), Inserm U1192, Lille, France.
  • Russell N; Department of Radiotherapy, The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis, Amsterdam, Netherlands.
  • Senkus E; Medical University of Gdansk, Gdansk, Poland.
  • Talbot JN; Institut National des Sciences et Techniques Nucléaires, CEA-Saclay, Paris, France.
  • Umutlu L; Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany.
  • Vandecaveye V; Department of Radiology, University Hospitals Leuven, Leuven, Belgium.
  • Verhoeff JJC; Department of Radiotherapy, University Medical Center Utrecht, Utrecht, Netherlands.
  • van Oordt WMH; Department of Medical Oncology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.
  • Zacho HD; Department of Nuclear Medicine, Aalborg University Hospital, Aalborg, Denmark.
  • Cardoso F; Breast Unit, Champalimaud Clinical Centre, Champalimaud Foundation, Lisbon, Portugal.
  • Fournier L; Université Paris Descartes Sorbonne Paris Cité, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France.
  • Van Duijnhoven F; Department of Surgical Oncology, The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis, Amsterdam, Netherlands.
  • Lecouvet FE; Department of Radiology, Institut de Recherche Expérimentale et Clinique (IREC), Cliniques Universitaires Saint-Luc, Institut du Cancer Roi Albert II, UCLouvain, Brussels, Belgium.
Lancet Oncol ; 24(8): e331-e343, 2023 08.
Article in En | MEDLINE | ID: mdl-37541279
ABSTRACT
Breast cancer remains the most common cause of cancer death among women. Despite its considerable histological and molecular heterogeneity, those characteristics are not distinguished in most definitions of oligometastatic disease and clinical trials of oligometastatic breast cancer. After an exhaustive review of the literature covering all aspects of oligometastatic breast cancer, 35 experts from the European Organisation for Research and Treatment of Cancer Imaging and Breast Cancer Groups elaborated a Delphi questionnaire aimed at offering consensus recommendations, including oligometastatic breast cancer definition, optimal diagnostic pathways, and clinical trials required to evaluate the effect of diagnostic imaging strategies and metastasis-directed therapies. The main recommendations are the introduction of modern imaging methods in metastatic screening for an earlier diagnosis of oligometastatic breast cancer and the development of prospective trials also considering the histological and molecular complexity of breast cancer. Strategies for the randomisation of imaging methods and therapeutic approaches in different subsets of patients are also addressed.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms Type of study: Clinical_trials / Diagnostic_studies / Guideline / Observational_studies Limits: Female / Humans Language: En Journal: Lancet Oncol Year: 2023 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms Type of study: Clinical_trials / Diagnostic_studies / Guideline / Observational_studies Limits: Female / Humans Language: En Journal: Lancet Oncol Year: 2023 Document type: Article